Family Growth

Located in Red Bank, NJ, Family Growth operates within the NJ regulatory framework as a licensed addiction-treatment provider. The facility's programming is outpatient (Outpatient), not residential. Structural evaluation of this facility's clinical posture requires review of state licensing records, accreditation status, and payer-network contracts.

Care levels at Family Growth

Level-of-care documentation: Family Growth is an outpatient-focused program (Outpatient) — patients live at home or in sober living and attend treatment sessions. This level of care is clinically appropriate for mild-to-moderate substance use disorder, or for patients stepping down from residential. Under MHPAEA 2024 medical-necessity criteria disclosure, plan-specific criteria for each of these levels must be available to patients upon request. Mismatch between documented clinical need and offered level of care is a common source of authorization denial.

Insurance and payment

Payment and insurance posture: Family Growth accepts both Medicaid and commercial insurance, which is the broadest payer profile and typically correlates with programs that operate at scale across the economic spectrum. Pre-admission Verification of Benefits (VOB) documentation should include: specific plan product and network status, deductible status at time of admission, coinsurance rate applicable, prior authorization status and turnaround, and out-of-pocket accumulation. Under MHPAEA 2024 disclosure rules, plan-specific medical-necessity criteria must be available on request.

Specialty programming

The facility's documented specialty programming includes: Clients who have experienced trauma, Persons with post-traumatic stress disorder (PTSD). Clinical verification of specialty programming should encompass credentialed staff profile, programming-hour documentation, and specialty-specific medical-necessity documentation for third-party authorization. The MHPAEA 2024 rule addresses specialty-program network adequacy for patients requiring specific clinical capabilities.

Before you call

Pre-admission due-diligence for Family Growth: (1) ASAM 4e level-of-care documentation matching clinical assessment; (2) written Verification of Benefits specific to insurance product; (3) MAT policy documentation (particularly buprenorphine and methadone continuation protocols for opioid use disorder patients); (4) accreditation verification via CARF or Joint Commission provider-search tools; (5) state licensing status confirmed via NJ behavioral-health regulator inspection records. If the clinical situation involves opioid use disorder, confirm explicitly whether Family Growth offers medication-assisted treatment — buprenorphine, methadone, or naltrexone. Programs that do not are operating outside the current standard of care.